| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 13, 2026 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2026 | $33.00 | Overweight | Barclays |
| 11/7/2025 | Underweight → Equal-Weight | Morgan Stanley | |
| 1/13/2025 | $40.00 → $15.00 | Outperform → Market Perform | BMO Capital Markets |
| 11/21/2024 | $8.00 | Underweight | Morgan Stanley |
| 9/23/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 4/15/2024 | $45.00 | Overweight | Barclays |
| 4/15/2024 | $459.00 | Overweight | Barclays |
| 2/7/2024 | $81.00 | Buy | Goldman |
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
Barclays resumed coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $33.00
Morgan Stanley upgraded 4D Molecular Therapeutics from Underweight to Equal-Weight
BMO Capital Markets downgraded 4D Molecular Therapeutics from Outperform to Market Perform and set a new price target of $15.00 from $40.00 previously
8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular d
EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 14, 2026, the compensation committee of the Company’s board of directors granted six new non-executive employees 37,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into emplo
EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Montreal, Canada, from July 15 - 18, 2026. ASRS 2026 Presentation Details: Title:2-Year Follow Up: PRISM Phase 2b Clinical Trial EvaluatingInvestigational 4D-150, an Intravitreal Gene Therapy, in aBroad Neovascular AMD PopulationDate/Time:Saturda
4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of PennsylvaniaAnnounces sCFH as payload for 4D-175 lead product candidate for geographic atrophy (GA); sCFH extensively characterized in 3 genetic mouse models and in non-human primates (NHP)CFH variants with reduced complement inhibitory function are a well-validated genetic risk factor for GA secondary to age-related macular degeneration (AMD), with approximately 75% of AMD patients carrying a high-risk variant of CFH; utilizing a precision medicine approach, this population represents a potential target population for 4D-175Continues expans
All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kgCardiac biopsy demonstrated selective and widespread transgene expression within ~50% of cardiomyocytes Engaging with FDA to lift clinical hold and resume enrollment with updated exclusion criteria and highly effective rituximab/sirolimus immunosuppressive regimen to reduce risk of atypical hemolytic uremic syndrome ("aHUS")Otherwise, generally well-tolerated with no liver, heart, or dorsal root ganglia ("DRG") toxicity observedCompany to host live webcast today at 4:30 p.m. EST EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 4D Mo
Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized anti-VEGF injection rate of ~11Following intravitreal 4D-150, Cohort 1 patients' annualized anti-VEGF injection rate was reduced by 96.7%80% of Cohort 1 patients had not received any supplemental aflibercept injections for up to ~10 months after 4D-150 dosingCohort 1 safety and tolerability of 4D-150 demonstrated to date, with no clinically significant intraocular inflammation or hypotony reportedConference call & webcast to be held Monday November 14, 2022 at 8:00 AM E.T. EMERYVILLE, Calif.
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of August Moretti to its board of directors. Concurrent with this appointment, the Company announced the retirement of Dr. Dean Baker from the board. "We are pleased to welcome August Moretti to our board at this transformative stage for Vivani," said Gregg Williams, Chairman of the Board. "His expertise will be instrumental as we advance our lead semaglutide implant, NPM-139, through clinical-stage development and continue to leverage our propriet
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company's financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives. Mr. Humer is an accomplished finance executive and biotechnology leader with more than two decades of experience
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)